Unlocking the infinite
potential of the brain
About us
Galmeon aims to revolutionise patient care by drawing on neuroscience to develop non-invasive therapeutic solutions.
Founded in 2025, Galmeon pays tribute to two pioneers in the history of neuroscience:
- Luigi Galvani (18th century), physicist and physician, pioneer of muscle electrophysiology
- Alcmeon of Croton (5th century BC), the first Greek physician to recognise the central role of the brain
We embody this continuity by combining historical foundations with technological innovation.
Our ambition: to harness the power of the brain to develop solutions that promote optimal quality of life.
Our mission
Our project was based on a powerful observation: the central role of the brain in the care pathway.
Galmeon addresses a real public health issue: accelerating the return to active life (professional or sporting).
We transform knowledge into innovation, and innovation into impact to build the healthcare of tomorrow.
Our Products
We develop software and hardware solutions that integrate AI to serve healthcare practitioners.
Our goal: to systematise the diagnosis of neuromotor alterations, offer personalised treatment solutions, and ensure patients’ progress is sustained.
These alterations, also known as Arthrogenic Muscle Inhibitions (AMI), are adaptive mechanisms implemented by the brain following trauma or surgery.
Initially natural, they persist in nearly half of all cases, leading to chronic motor disorders and rehabilitation setbacks.
Early identification and treatment are therefore essential.
We are guided by strong values:
- a strong scientific culture, based on rigorous research protocols
- a technological approach integrating neuroscience and personalised data analysis using artificial intelligence (AI)
- the desire to develop our innovative technologies in France
We are developing technology that enables healthcare practitioners (orthopaedic surgeons, sports doctors, physiotherapists, osteopaths) to detect motor impairments in a standardised manner before and after surgery.
Early identification of this phenomenon makes it possible to propose an appropriate treatment protocol.
We are developing a solution for treating neuromotor disorders (musculoskeletal disorders, neurology, urology, TMJ) by combining motor imaging with low-frequency sound therapy.
Based on the principles of Allyane Therapy, this software solution supports practitioners throughout their sessions, ensuring effective, reproducible and sustainable care thanks to patient monitoring.
We develop software that enables healthcare practitioners to track their patients’ progress and attendance in order to maximise the results of the session.
The team
Cyrille FLEURY
President
Cyrille has held executive positions in publicly traded companies and chaired the Menix Group, a French mid-sized company. Passionate about innovation, he has deployed digital solutions in the fields of orthopaedic and dental surgery in France and internationally.
Cyrille sits on the boards of healthcare companies and on the SNITEM board of directors.
Stéphane UNG
CEO
Stéphane has held sales management positions in companies in the orthopaedic surgery industry, ranging from SMEs to publicly traded companies.
During his career, Stéphane has notably supported their international expansion by developing sales activities and opening subsidiaries in Europe and the United States.
Scientific Advisory Board
Aymeric GUILLOT
University professor
Aymeric has been a researcher in neurophysiology for over twenty years, specialising in the study of visualisation and motor imagery to improve performance, both in athletes and in rehabilitation. His work explores the neuroplasticity induced by mental training and develops tools to accurately measure its effects.
Recognised nationally and internationally, his research combines fundamental neuroscience with clinical and sports applications.
Dr Romain LOURSAC
Sports physician, physician for the LOU Rugby professional team
Aymeric has been a researcher in neurophysiology for over twenty years, specialising in the study of visualisation and motor imagery to improve performance, both in athletes and in rehabilitation. His work explores the neuroplasticity induced by mental training and develops tools to accurately measure its effects.
Recognised nationally and internationally, his research combines fundamental neuroscience with clinical and sports applications.